- Location
Sclerosis Treatment
"-
Genzyme Has Obtained an Approval From Health Canada for Its Lemtrada
Dec 17, 2013Genzyme, a Sanofi company, has obtained an approval from Health Canada for its Lemtrada (alemtuzumab) for the treatment of relapsing remitting multiple sclerosis (RRMS). Health Canada has approved Lemtrada for the management of adult ...
-
ALS-ETF, Denovo Have Entered Into Partnership to Explore Using Denovo's Technology
May 15, 2013The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have entered into partnership to explore using Denovo's technology to identify potential responder groups for drugs that are being studied in patients suffering from ...
-
Mapi Pharma Has Been Granted a US Patent for a Long Acting Depot Formulation
May 9, 2013Mapi Pharma, developer of complex bulk Active Pharmaceutical Ingredients (APIs), has been granted a US patent for a long acting depot formulation of glatiramer acetate, which is under the development as a once-a-month treatment for Multiple ...
-
Neuralstem Has Obtained Notice of Allowance for a Patent
Apr 8, 2013Neuralstem has obtained notice of allowance for a patent that covers various methods to use expanded spinal cord stem cells such as NSI-566 to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The company completed Phase ...
-
Nuron Biotech Has Secured $80m Finance to Support The Commercialization and Expansion
Dec 22, 2012Nuron Biotech has secured $80m finance from HealthCare Royalty Partners to support the commercialization and expansion of its Meningitec, a recently acquired vaccine from Pfizer. Meningitec is an established commercial vaccine to prevent ...
Tags: Nuron Biotech, secured finance, vaccine, Meningitec, commercial vaccine
